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Abstract
Background:Many cystic fibrosis (CF) patients chronically infected with Pseudomonas
aeruginosa are on maintenance tobramycin inhalation therapy. Cough is reported as a
side effect of tobramycin inhalation powder (TIP) in 48% of the patients. Objectives
of this study were to investigate the association between the inspiratory flow of TIP
and cough and to study the inhalation technique. We hypothesized that cough is
related to a fast inhalation.
Materials and Methods: In this prospective observational study, CF patients ≥6 years
old on TIP maintenance therapy from four Dutch CF centers were visited twice at home.
Video recordings were obtained and peak inspiratory flow (PIF) was recorded while
patients inhaled TIP. Between the two home visits, the patients made three additional
videos. CF questionnaire‐revised, spirometry data, and computed tomography scan were
collected. Two observers scored the videos for PIF, cough, and mistakes in inhalation
technique. The associations between PIF and cough were analyzed using a logistic mixed‐
effects model accounting for FEV1% predicted and capsule number.
Results: Twenty patients were included, median age 22 (18–28) years. No significant
associations were found between PIF and cough. The risk of cough was highest after
inhalation of the first capsule when compared to the second, third, and fourth capsule
(P ≤ .015). Fourteen patients (70%) coughed at least once during TIP inhalation. A
breath‐hold of less than 5 seconds after inhalation and no deep expiration before
inhalation were the most commonly observed mistakes.
Conclusion: PIF is not related to cough in CF patients using TIP.
K E YWORD S
cough, cystic fibrosis, dry powder inhaler, inhalation, tobramycin
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
1 | INTRODUCTION
Cystic fibrosis (CF) is a genetic disorder characterized by severe
chronic lung disease. The mucus of CF patients is thickened, resulting
in impaired clearance of pathogens.1 Patients with CF suffer from
chronic infections and increased inflammatory response in the lungs.
This causes irreversible lung damage, resulting in a reduced quality of
life, and a shortened life span.1 Pseudomonas aeruginosa is the most
predominant pathogen that causes progressive lung disease.2 The
overall prevalence of chronic infection with P. aeruginosa in 2016 was
around 30% in Europe and the United States of America.3,4
Suppressive inhalation antibiotic therapy is a standard treatment for
patients with chronic P. aeruginosa infection: The guidelines of the
United States of America recommend long‐term use of tobramycin
inhalation solution (TIS) as the first‐line choice, and the more recent
European guidelines add that TIS and tobramycin inhalation powder
(TIP) is equally effective. Alternatively, options are aztreonam lysine
(both guidelines) and colistin (European guidelines).5-7 Nebulization
therapy comes with some disadvantages: it is time‐consuming,
nebulizers are in general not easy to carry around, need disinfection
after each use, and require periodic technical maintenance.8 To
overcome these disadvantages, TIP was developed. TIP is administered
with the T‐326 inhaler (Tobi Podhaler™; Novartis Pharma AG, Basel,
Switzerland). A full dose of TIP contains four capsules of 50mg each
(28mg tobramycin + 22mg excipients). It is advised to inhale each
capsule at least twice. Like TIS, TIP is administered twice daily. The
administration time of TIP is one‐third of that of TIS, the T‐326 inhaler
is pocket‐size, and does not require extensive post‐use cleaning or
technical maintenance.9,10 Importantly, TIP has shown to be noninferior
compared to TIS in terms of reducing exacerbations and P. aeruginosa
colony‐forming units. In addition, higher treatment satisfaction was
reported for TIP compared to TIS.9 However, a disadvantage of TIP is
the occurrence of cough immediately after inhalation. In the pivotal
noninferiority study comparing TIS and TIP, the cough was reported in
48% of patients using TIP (n = 308) compared to 31% using TIS
(n = 209).9 The authors did not mention specific instructions given to
patients with regard to an inspiratory flow. TIP particles might induce a
cough reaction for various reasons: First of all, TIP particles are dry
where TIS particles are wet. Second, TIP particles might hit the throat
wall with greater impact, due to the relatively faster inhalation of TIP
compared to TIS. The T‐326 inhaler has a low‐to‐medium resistance
(approximately 0.08 [cm H2O]
½/[L/min]), fast inspiratory flows between
40 up to 115 L/min were observed in a laboratory setting when inhaling
TIP.11 On the contrary, TIS is inhaled with tidal volume breathing. Third,
tobramycin sputum concentrations were found to be double after
inhalation of TIP compared to that of TIS.9 This might be a result of
higher upper airway deposition. Importantly, according to an in vitro
study by Haynes et al,11 the total lung dose of TIP is independent of
inspiratory flow.
It is unknown which inspiratory flows are generated by patients
for routine use of TIP in the home setting. Furthermore, we do not
know what the prevalence of cough is in the home setting, nor
whether correct inhalation techniques are being used.
The primary objective of our study was to record TIP inhalations
by CF patients on video in the home setting and to study the
association between inspiratory flow and cough. We hypothesized
that a faster inhalation maneuver by patients would increase the risk
of cough. Secondary objectives were (a) to assess the percentage of
patients that coughed after inhaling TIP, and (b) to study mistakes in
the inhalation technique of TIP inhalations. In a multicentre,
prospective observational study, we assessed inhalation maneuvers
and the relation with cough for TIP in the home setting.
2 | MATERIALS AND METHODS
2.1 | Study population
Patients were recruited from four CF centers in the Netherlands:
Erasmus Medical Center in Rotterdam, Haga Hospital in The Hague,
University Medical Center Utrecht and Academic Medical Center in
Amsterdam.
Inclusion criteria:
1. Proven diagnosis with CF.
2. Minimum age of 6 years.
3. Maintenance treatment with TIP for at least 1 month.
Exclusion criteria:
1. Respiratory exacerbation requiring intravenous treatment with
antibiotics at the time of inclusion or during the study period.
2. Any medical condition that increases the risk of cough according
to the treating physician, not directly related to CF lung disease
(ie, otitis media).
3. Unable to understand and execute instructions.
Informed consent was obtained from both parents if the patient
was younger than 12 years, from the patient and both parents if the
patient’s age was between 12 to 18 years, and only from the patient
if the patient was 18 years and older. This study was approved by the
Institutional Review Board of the Erasmus Medical Center (MEC‐
2015‐329).
2.2 | Study design
The study design is shown in Figure 1. The study consisted of five
study moments: two home visits by an investigator (JM) and three
video recordings by the patient between the home visits.
During the first home visit (visit 1), the patient inhaled a full dose
of TIP without any instructions, while being recorded on video by the
investigator (video S1). Inspiratory flow patterns of the first
inhalation of the third capsule were measured with an inspiratory
profile recorder (IPR). When inhaling the third capsule, we assumed
the patient was used to the situation, and the fourth capsule could be
used if measurements failed. Furthermore, the patient received
instructions to record himself/herself on video on three separate
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days while inhaling a full dose of four TIP capsules (self‐recorded
video 1, 2, and 3). The investigator and patient together looked for a
suitable place to record, and a video‐camera including a tripod was
left behind with the patient.
During the second home visit (visit 2), the patient also inhaled a
full dose of TIP while being recorded on video by the investigator.
However, the patient was randomized and instructed to either inhale
the first capsule slowly and the second capsule fast, or vice versa. The
inspiratory flows of the first two capsules were recorded with
the IPR, and if the recordings failed, the third and fourth capsule
were recorded with the same instructions. Otherwise, the third and
fourth capsule were inhaled as usual and not recorded with the IPR.
In case the investigator noticed any mistakes in the inhalation
technique, this was recorded and discussed with the patient after
completion of all study proceedings.
Importantly, except for the instructed fast and slow inhalation of
visit 2, the patients were asked to inhale TIP the way they would
normally do.
Patient demographics (age, sex, duration of treatment) were
collected at visit 1. Chest computed tomography (CT) scans
were collected when available and made within 24 months before
inclusion. Structural changes on CT scans were analyzed using the
PRAGMA‐CF scoring method.12 The highest forced expiratory
volume in 1 second (FEV1) measured within 12 months before
inclusion and the forced vital capacity (FVC) were collected. Both
values were expressed as a percentage of predicted values.13
2.3 | Inhalation measurements
The IPR measured the dynamic pressure drop at the mouthpiece of
the inhaler during inhalation and converted the data to inspiratory
flow in L/min.11 The peak inspiratory flow (PIF) was used to analyze
the association between inspiratory flow and cough, to which we
refer as “recorded PIF.” Furthermore, inhaled volume and flow
acceleration were extracted from these recorded measurements.
2.4 | Standardization of video scoring
The estimated PIF was independently assessed by two observers (JM
and MA). The observers were trained as follows: First, reference
videos were made of a slow (40 L/min or less), medium (40‐85 L/min),
and fast (85 L/min or higher) inhalation, referring to the PIF. Next, a
practice batch of videos was made for which 20 volunteers
performed one inhalation with an empty TIP capsule. The volunteers
were at random instructed to inhale slow, medium or fast. The two
observers, blinded for these instructions, scored the estimated PIF of
this practice batch. The agreement between the observers on the
estimated PIF of this practice batch was 80%. To standardize the
assessment of inhalation technique, both observers scored 10 videos
made for a previous study by Bos et al,14 in which patients inhaled
using various nebulizers. Although the inhalation maneuvers of
nebulizers and TIP differ, some of the technique items “lips sealed
around the mouthpiece,” “upright position during inhalation”, and “a
horizontal position of the inhaler” could be practised.
All videos were renamed and randomized, and scored by both
observers. Because the T‐326 inhaler has a distinctive rattle
depending on inspiratory flow, scoring was performed using a high‐
quality active noise‐canceling headset.
Nonmatching scores for estimated PIFs and cough were discussed
during a consensus meeting to come upon a final score. Nonmatching
scores for inhalation technique were not discussed during the consensus
meeting since these were no main outcome parameters. For these latter
scores, the mean of both observers was calculated.
2.5 | Checklist video recordings
Every inhalation was scored using a checklist that contained the
following items:
1. Estimated PIFs: slow, medium, or fast.
2. Occurrence and moment of cough (during inhalation, breath‐hold,
exhalation or afterward).
3. Inhalation technique. These items were derived from the
manufacturers’ instructions: deep exhalation before inhalation,
exhalation outside of the inhaler, lips sealed around the mouth-
piece, upright position during inhalation, a horizontal position of
the inhaler, and breath‐hold ≥5 seconds after inhalation.
2.6 | Statistical analysis
Descriptive data are expressed as median with interquartile ranges
(IQR), as numbers and as percentages (%).
To analyse the association between cough and PIF, a McNemar test
was planned to compute the difference between the risk of cough after a
slow inhalation (assuming pcough = lowest reported cough rate, 0.10)
15 and
a fast inhalation (assuming pcough = highest reported cough rate, 0.48)
9
resulting in a sample size of 30 patients. However, in total only 20
F IGURE 1 Study design. Patients were
visited twice by an investigator. On three
separate days in between, the patients
were asked to record their inhalations on
video. CFQ‐R, cystic fibrosis questionnaire‐
revised; TIP, tobramycin inhalation powder
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patients were included and the performed instructed inhalations (slow
and fast) did not meet the study definitions (slow PIF <35 L/min, fast
PIF >85 L/min) for which reasons the McNemar was not appropriate.
Instead, two analyses were performed using logistic mixed‐effects
models, to correct for other variables while investigating the association
of PIF and cough, accounting for multiple measurements per patient:
analysis 1 was performed to study the association between all recorded
PIFs and cough, and analysis 2 to study the association between the all
estimated PIFs and cough. For this latter analysis, estimated PIFs were
collected of visit 1, and self‐recorded videos 1, 2, and 3. The estimated
PIFs of visit 2 were excluded, because they included instructed
inhalations which could bias results.
For both analyses, only the first inhalation of each capsule was
included, as some capsules (25%) were only inhaled once. We accounted
for FEV1% predicted as we assumed that lung function would be a
confounding factor. In analysis 2, we added the capsule number to our
model, as this showed to be a confounder.
Additionally, with mixed‐effects model analyses the relation
between inhaled volume (accounting for FEV1% predicted and
height) and cough, and between flow acceleration (accounting for
FEV1% predicted) and cough were assessed.
To determine the prevalence of cough after the inhalation of TIP,
we assumed each capsule of TIP would be empty after two
inhalations.16 Therefore, only data of the first, and if present, the
second inhalation per capsule are presented. Also for this analysis,
visit 2 videos were excluded as they contained instructed inhalations
which could bias the results.
Mistakes made in the inhalation technique are presented as mean
percentages of both observers. All inhalations were included and
overall technique scores were calculated as follows: for each
checklist item on inhalation technique, one point was assigned per
item when executed correctly, and scores of both observers were
added. The mean technique score was expressed as a percentage of
the maximum score. The differences in inhalation technique between
the videos with and without the presence of the investigator were
calculated with the Wilcoxon signed‐rank test.
To assess the interobserver and intraobserver agreement of the
checklist items Cohen’s kappa was calculated. The interobserver
agreement was calculated for all inhalations. The intraobserver
agreement was calculated after each observer rescored 20 randomly
selected videos. We interpret Cohen’s kappa values as follows: poor
(<0), slight (0‐0.20), fair (0.21‐0.40), moderate (0.41‐0.60), substantial
(0.61‐0.80), and almost perfect (>0.81).17
Statistical analyses were performed using SPSS version 24.0 and
R version 3.4.3. The significance level was defined as P < .05.
3 | RESULTS
3.1 | Study population
We approached 55 eligible patients, of whom 20 patients were
included. Characteristics of the study patients are summarized in
Table 1. Sixteen adults (80%) and four children (20%) were included,
of whom 13 (65%) were male. Seventeen patients (85%) used TIP
month‐on month‐off, three patients (15%) used TIP continuously, and
the median duration of treatment at the time of participation was 19
months. Details of the PRAGMA‐CF scores and CFQ‐R scores are
presented in Tables S1 and S2.
3.2 | Association between recorded PIF and cough
Recorded PIFs of an uninstructed, instructed fast, and instructed slow
inhalation were obtained from 19 patients, resulting in 57 measurements.
Data of one patient were lost in the data transfer process. Figure 2 shows
a scatter plot of the recorded PIFs in L/min in relation to the outcome
TABLE 1 Patient characteristics
Characteristic Values Outcome
Age (y) Median (IQR) 22 (18–28)
Male sex n (%) 13 (65)
Use of TIP (mo) Median (IQR) 19 (11–53)
PRAGMA‐CF CT analyses
Total disease score (%) (n = 12) Median (IQR) 9 (7–17)a
Trapped air score (%) (n = 11) Median (IQR) 17 (1–30)a
Spirometry
FEV1% predicted Median (IQR) 82 (62–100)
FVC % predicted Median (IQR) 98 (83–106)
Abbreviations: CT, computed tomography; FEV1, forced expiratory
volume in 1 second; FVC, forced vital capacity; IQR, interquartile range;
TIP, tobramycin inhalation powder.
aExpressed as a percentage of the total lung volume. In total 20 patients
were included.
F IGURE 2 Scatter plot of recorded peak inspiratory flows (PIF).
This scatter plot shows the recorded PIF in relation to cough and the
forced expiratory volume in one second (FEV1) % predicted. The
x‐axis shows the FEV1% predicted and the y‐axis shows the PIF in
liter per minute. The circles represent the inhalations without cough
and the crosses represent the inhalations with cough. Three
inhalations per patient were obtained, of 19 patients (data missing of
one patient); resulting in 57 measurements. FEV1, forced expiratory
volume in one second
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cough and to FEV1% predicted, in which no association could be detected.
In line with the interpretation of the scatter plot, the mixed‐effects model
analysis showed no association between the recorded PIF and cough
(P= .182) (Table 2). The additional analyses showed that inhaled volume
and flow acceleration were also not associated with cough (P= .506
and.138) (Table S3).
3.3 | Association between estimated PIF and cough
We obtained 319 estimated PIFs. For one patient the inhalation of one
capsule was missing on one of the self‐recorded videos. Initially, the
mixed‐effects model analysis was performed without accounting for
capsule number, and then it seemed that a fast PIF significantly reduced
the risk of cough (P= .039). However, we identified capsule number as a
significant confounder and therefore added this to our model. We found
no significant association between the estimated PIF and cough
(P medium inhalation = .080 and P fast inhalation = .094) (Table 2).
However, the risk of cough is significantly lower for the second, third, and
fourth capsule compared to the first capsule (P< .001, P= .015, and
P< .001, respectively).
3.4 | Prevalence of cough
A total of 319‐first and 240‐second inhalations of the capsules were
analyzed on the visit 1 and self‐recorded videos. The prevalence of
cough per estimated PIF of the first inhalation was 22% (slow), 28%
(medium), and 29% (fast). The first inhalation of the first capsule
resulted in cough in 42% of the inhalations, compared to 22%, 26%,
and 16% for the second, third, and fourth capsule. Forty‐eight % of
the inhalations were performed with a medium PIF, 28% with a slow
PIF, and 25% with a fast PIF. Fourteen patients (70%) coughed at
least once. The patients coughed during inhalation in 27% of the
cases, during breath‐hold in 17%, during exhalation in 32%, and after
exhalation in 24% of the cases.
Of 319 inhaled capsules, 25% of the capsules were inhaled only
once, 54% were inhaled twice, 13% were inhaled three times, and 9%
of the capsules were inhaled four up to seven times.
3.5 | Inhalation technique
The inhalation technique varied widely among patients. The
median (IQR) total score for all patients on the inhalation
technique was 75 (71–92). Table S4 shows the median (IQR)
scores on inhalation technique per patient. One patient was
excluded from this analysis because of the low quality of the self‐
recorded videos.
The mean prevalence of both observers for each mistake in the
inhalation technique of all 828 inhalations is shown in Figure 3.
Most commonly made mistakes were a breath‐hold after inhalation
less than 5 seconds (54% and 52% of the inhalations according to
observer 1 and 2, respectively), followed by an inhalation that
was not preceded by a complete exhalation (54% and 22%). The
presence of an investigator was not of influence on the inhalation
technique (P = .133).
3.6 | Interobserver and intraobserver agreement
Table S5 shows Cohen’s kappa for the interobserver and intraob-
server agreement. The interobserver agreement was fair (0.29‐0.36)
for the items deep exhalation, exhalation outside the inhaler, upright
TABLE 2 Output mixed model analyses for association between
cough and recorded and estimated peak inspiratory flow
Recorded PIF
(n = 57)
Effect
(log odds)
Standard error
(log odds) P
Baseline −0.38 5.20
PIF (L/min) 0.02 0.04 .182
FEV1 (% predicted) −0.01 0.06 .616
Estimated PIF
(n = 319)
Effect (log
odds)
Standard error
(log odds) P
Baselinea 2.24 3.08
PIF
Medium −0.96 1.15 .080
Fast −1.12 1.39 .094
FEV1 (% predicted) −0.02 0.04 .149
Capsule number
Second capsule −0.88 0.53 <.001*
Third capsule −0.56 0.50 .015*
Fourth capsule −1.17 0.58 <.001*
Note: This table shows the output of the mixed model analysis to study the
association between cough and recorded and estimated PIF. FEV1 %
predicted was added to both models as possible confounder. In the
analysis of the estimated PIF, the capsule number was also added as this
was a significant confounder.
Abbreviation: FEV1, forced expiratory volume in one second.
aA slow inhalation of the first capsule and FEV1 % predicted of 0 is
baseline.
*P < 0.05.
F IGURE 3 Bar chart of mistakes of inhalation technique. This bar
chart presents the mean prevalence of the two observers of mistakes
made in the inhalation technique while inhaling tobramycin
inhalation powder. All inhalations captured on video were used for
this analysis (n = 828).
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position of the patient, and horizontal position of the inhaler.
The interobserver score on estimated PIF was moderate (0.48),
however, disagreement on PIF was solved during consensus meet-
ings. One observer scored systematically more mistakes than the
other observer. The intraobserver was for moderate for three items
of one observer, while the remaining scores were substantial or
almost perfect.
4 | DISCUSSION
With this multicentre observational study, we assessed whether
cough after inhalation of TIP is associated with the inspiratory flow.
The inspiratory flow was assessed using objective measurements of
the PIF and was estimated using video registrations.
We did not find a significant relation between recorded nor
estimated PIF and cough, even though cough occurred frequently.
Our estimated PIF analysis initially showed that a fast inhalation
reduced the risk of cough. However, the order of capsules was a
significant confounder, and when accounting for the order of the
capsules, the correlation between estimated PIF and cough dis-
appeared. The first capsule resulted in more cough than the second,
third, and fourth (P ≤ .015). It is well possible that patients inhale the
first capsule more slowly than the consecutive capsules in their
attempt to reduce cough. Then, once they have managed the first
inhalations, they are more confident and start inhaling faster, which
results in counterintuitive associations of more cough for the slower
inhalations.
With a post hoc analysis of the IPR data, we did not find an
association between inhaled volume and cough or the acceleration of
flow and cough.
Around two‐thirds of patients coughed at least once after
inhaling TIP. The reported prevalence of cough for TIP in the
literature is in general lower and varies between 10% and 48%.9,15
An explanation for our higher numbers is that we used video
registrations while in the referred studies only adverse event
registrations from emergency care visits (which indicates very severe
cough), or self‐reporting surveys were used. Self‐reporting surveys
are known to suffer from recall bias. Hence, we think our numbers
are likely to be more realistic.
The video recordings of TIP inhalations provided a unique
opportunity to assess the inhalation technique of the patients. Two
relevant mistakes in inhalation technique were most frequently
observed: half of the inhalations showed a breath‐hold of fewer than
5 seconds, and two‐fifths of patients did not perform a deep
exhalation before inhalation. Of note is that when cough occurred,
patients were often unable to hold their breath for at least 5 seconds.
Both these mistakes are likely to reduce the efficiency of drug
deposition in the small airways. Importantly, proper instruction of the
patient and repeated (video) evaluation of inhalation technique offers
a great opportunity to reduce the prevalence of mistakes empower-
ing patients to get the most out of their inhalation treatment.
A strength of our study is the large number of supervised and
unsupervised video registrations in the home setting. We believe to
have obtained a realistic impression of the use of TIP that is
reflecting daily life practice. Another strength was the thorough
observation of all videos by two observers, providing detailed
information on both (estimated) inspiratory flow and inhalation
technique.
A limitation of the study is the relatively small sample size.
The planned statistical test (McNemar) was not performed and
instead, we used the more complex mixed‐effects model. An
important advantage of this analysis is the chance to correct for
multiple measurements within patients and to add confounders.
Due to a large number of observations and the lack of association
in both the raw data plot and both mixed‐effects models we
believe that the lack of association between inspiratory flow and
cough in our study population indicates that the occurrence of
cough might be explained by other factors than inspiratory flow.
A possible explanation that was not studied, is adherence to
treatment. A hypothesis is that the patient who is more compliant
gets used to TIP, and as a result, suffers less from cough. Another
factor that might be related to cough is respiratory effort during
inhalation, which has been measured in CF patients using
electromyogram.18
Another limitation of the study is that observer 1 was somewhat
stricter in scoring inhalation technique than observer 2. However,
the intraobserver agreement was good for most scored items which
is an important condition for a robust statistical analysis. For future
similar studies, the interobserver variability can be further improved
by using training material specifically developed for dry powder
inhalers.
Instead of estimating the PIF, the flow analysis could have been
optimized by using the IPR in all observations. Alternatively,
automated sound analysis has been described in other studies to
successfully perform flow analysis.19 However, the primary aim of
this current study was to observe inhalation in a real‐life situation,
even without the presence of an investigator. The methods described
above would have interfered with this aim. Therefore, although we
realize that it is at the expense of precision, we choose not to add
more advantaged analysis methods.
The final remark on the technique scores is that all steps were
weighted equally. Consequently, inhalations of patients with similar
overall technique scores might not be equally effective.
5 | CONCLUSION
In summary, cough immediately after inhalation of the first capsule is
a common side effect of TIP. Less cough occurs after inhalation of the
consecutive capsules. Cough was not related to inspiratory flow.
Furthermore, we found that inhalation techniques are often
suboptimal, and therefore periodical counseling is highly recom-
mended to optimize the treatment effect of TIP.
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